Week in Review: Grifols Pays $1.9 Billion for 26% Stake in Shanghai RAAS

Deals and Financings • Grifols of Barcelona acquired a 26% stake in Shanghai RAAS, one of China's largest blood plasma companies, for $1.9 billion; • Ambrx, a San Diego biopharma owned by four China investors, signed a $475 million agreement to discover novel protein drugs with Beijing's BeiGene; • South Korea's ABL Biotechnologies will pay up to $220 million for rights to use WuXi Biologics' discovery platforms to discover multiple bispecific antibodies; • 3SBio of Shenyang will make $50 million in upfront payments, plus milestones, for China rights to commercialize two Taiwan Liposome products; Company News • Novo Nordisk launched INNOVO, a platform designed to promote innovation by connecting Novo Nordisk with China academic institutions, bio-tech startups and incubators; Trials and Approvals • CASI Pharma was approved to begin a China registrational clinical trial of Marqibo®, an in-licensed leukemia drug; • I-Mab Biopharma of Suzhou began a China Phase Ib/IIa clinical trial of an Interleukin-7 fusion protein in patients with advanced solid tumors; Government and Regulatory • China regulators published final rules governing IPOs on its new Shanghai High-Tech Board for young companies, with five sets of financial listing criteria, including a pre-revenue option. Stock Symbols: (MCE: GRF, MCE: NSDQ: GRFS) (SHZ: 002252) (NSDQ: BGNE; HK: 06160) (KS: 298380) (HK: 2269) (HK: 1530) (NSDQ: TLC, TWO: 4152) (NYSE: NVO) (NSDQ: CASI) Share this with colleagues: // //